Integrin-targeted therapies branch out

Small-molecule integrin inhibitors are catching the attention of pharmaceutical firms, with fibrosis joining gut dysfunction as a key indication for integrin-based interventions.

Search for this author in:

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Updates & Corrections

  • Correction 16 October 2020: The names of the companies Morphic Therapeutic and RGDscience have been corrected.

Nature Briefing

An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.